EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Serum a-1 Antitrypsin as a Novel Biomarker in Chronic Heart Failure

Ying-Ying Zheng, Ting-Ting Wu, Xian-Geng Hou, Hai-Tao Yang, Yi Yang, Wen-Juan Xiu, Ying Pan, Yi-Tong Ma, Ailiman Mahemuti, Xiang Xie iD

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14451 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Ying-Ying Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, No. 137, Liyushan Road, Urumqi, 830011, Xinjiang, China. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Excellent Youth Fund of Henan Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chronic heart failure (CHF) remains a major health issue worldwide. In the present study, we aimed to identify novel circulating biomarkers for CHF using serum proteomics technology and to validate the biomarker in three independent cohorts. Methods and results The isobaric tags for relative and absolute quantitation technology was utilized to identify the potential biomarkers of CHF. The validation was conducted in three independent cohort. Cohort A included 223 patients with ischaemic heart disease (IHD) and 321 patients with ischaemic heart failure (IHF) from the CORFCHD-PCI study. Cohort B recruited 817 patients with IHD and 1139 patients with IHF from the PRACTICE study. Cohort C enrolled 559 non-ischaemic heart disease patients with CHF (n = 316) or without CHF (n = 243). We found the expression of a-1 antitrypsin (AAT) was elevated significantly in patients with CHF compared with that in the patients with stable IHD using statistical and bioinformatics analyses. In a validation study, there was a significant difference between patients with stable IHD and patients with IHF in AAT concentration either in cohort A (1.35 ± 0.40 vs. 1.64 ± 0.56, P < 0.001) or in cohort B (1.37 ± 0.42 vs. 1.70 ± 0.48, P < 0.001). The area under the receiver operating characteristic curve was 0.70 [95% confidence interval (CI): 0.66 to 0.74, P < 0.001] in cohort A and 0.74 (95% CI: 0.72 to 0.76, P < 0.001) in cohort B. Furthermore, AAT was negative correlated with left ventricular ejection fraction (r = −0.261, P < 0.001). After adjusting for confounders using a multivariate logistic regression analysis, AAT remained an independent association with CHF in both cohort A (OR = 3.14, 95% CI: 1.667 to 5.90, P < 0.001) and cohort B (OR = 4.10, 95% CI: 2.97 to 5.65, P < 0.001). This association was also validated in cohort C (OR = 1.86, 95% CI: 1.02 to 3.38, P = 0.043).

Conclusions

The present study suggests that serum AAT is a reliable biomarker for CHF in a Chinese population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-AntitrypsinHeart FailureAgedFemaleHumansMaleMiddle AgedBiomarkersChronic DiseasePrognosisProteomicsROC CurveStroke VolumeObservational Studies as TopicEast Asian People

Stichwörter der Autor:innen

A-1 antitrypsinBiomarkerChronic heart failureIschaemic heart diseaseProteomics

Substanzen

alpha 1-AntitrypsinBiomarkers

Autor:innen und Institutionen

  • Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, No. 137, Liyushan Road, Urumqi, 830011, Xinjiang, China.

ORCID-Profile: Xiang Xie

Förderung

  • National Natural Science Foundation of China
  • Excellent Youth Fund of Henan Natural Science Foundation

Zitieren

APA

Zheng, Y. Y., Wu, T. T., Hou, X. G., Yang, H. T., Yang, Y., Xiu, W. J., Pan, Y., Ma, Y. T., Mahemuti, A., & Xie, X. (2023). Serum a-1 Antitrypsin as a Novel Biomarker in Chronic Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.14451

Vancouver

Zheng YY, Wu TT, Hou XG, Yang HT, Yang Y, Xiu WJ, et al. Serum a-1 Antitrypsin as a Novel Biomarker in Chronic Heart Failure. ESC Heart Failure. 2023. doi:10.1002/ehf2.14451

BibTeX
@article{Zheng2023,
  author = {Zheng, Ying-Ying and Wu, Ting-Ting and Hou, Xian-Geng and Yang, Hai-Tao and Yang, Yi and Xiu, Wen-Juan and Pan, Ying and Ma, Yi-Tong and Mahemuti, Ailiman and Xie, Xiang},
  title = {Serum a-1 Antitrypsin as a Novel Biomarker in Chronic Heart Failure},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14451}
}
Kostenlos starten →